Collaboration based on Valo’s large human dataset and computation powered by artificial intelligence.

Image Credit: Adobe Stock Images/Shutter2U

Novo Nordisk and Valo Health revealed that they have struck a deal to discover and develop novel treatments for cardiometabolic diseases based on Valo’s large human dataset and computation powered by artificial intelligence (AI). According to Novo Nordisk, this will include access to real-world patient data, AI-enabled small molecule discovery and Biowire human tissue modeling platform designed to speed up the discovery and development process.
As per terms of the deal, Valo will receive an upfront payment and a potential near-term milestone payment of $60 million, with the potential to earn additional milestone payments up to $2.7 billion, plus R&D funding and potential royalty payments.
“Artificial Intelligence and machine learning hold the promise to positively impact drug discovery and development, in particular enabling our vision of leveraging human datasets early in the process, which should lead to a better understanding of target biology,” said Marcus Schindler, EVP, chief scientific officer, Novo Nordisk. “Valo brings a differentiated and powerful approach to using these technologies on real-world human data to generate new insights and translate them into potential therapeutics for the benefit of patients suffering from cardiometabolic conditions. I am very much looking forward to our collaboration.”